Martin Delaney Collaboratories
The Martin Delaney Collaboratories for HIV Cure Research is the flagship NIH program on HIV cure research. The purpose is to foster dynamic, multidisciplinary collaborations between basic, applied, and clinical researchers studying HIV persistence and developing potential curative strategies. This is accomplished by establishing partnerships across academia, industry, government, and community, with a goal of leveraging common resources to accelerate the pace of HIV cure research and engage the next generation of HIV cure researchers.
The program was launched in July 2011 with the funding of three Collaboratories: CARE, DARE, and defeatHIV. In July 2016, the program was expanded to include three additional Collaboratories (BELIEVE, BEAT-HIV, and I4C) for a total of six Collaboratories. In 2021, the program was further expanded to include a total of 10 Collaboratories (CARE, DARE, BEAT-HIV, I4C, REACH, ERASE-HIV, CRISPR for Cure, PAVE, RID-HIV, and HOPE), with one of them (PAVE) focused specifically on HIV cure research in infants and children. The combined program supports a network of approximately 300 Collaboratory members.
REACH grant number: 1UM1AI164565
MDC Programs Awarded 2021-2026
Funding
The National Institutes of Health has awarded approximately $53 million in annual funding over the next five years to 10 research organizations in a continued effort to find a cure for HIV. The new awards for the Martin Delaney Collaboratories for HIV Cure Research program further expand the initiative’s 2016 renewal from 6 institutions to 10, and represent a funding increase of approximately 75 percent.
These awards are supported by the following NIH co-funding Institutes: National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Diabetes And Digestive And Kidney Diseases (NIDDK), National Institute Of Neurological Disorders And Stroke (NINDS), National Institute On Drug Abuse (NIDA), National Heart, Lung, And Blood Institute (NHLBI), and National Institute of Mental Health (NIMH)
About Martin Delaney
Martin "Marty" Delaney was an internationally recognized advocate for HIV/AIDS treatments, and led successful efforts to streamline the US Food and Drug Administration's drug approval process - efforts which have been credited with getting new and promising therapies to patients faster, likely leading to thousands of lives being saved.
In 1985 he founded Project Inform, an education and public policy advocacy group which he continued to lead as its Director until 2008. The work of Project Inform helped to found the community-based HIV research movement, helped to proliferate HIV treatment education and make it available to patients and care providers, and lead a national movement to accelerate approval by the FDA of critical drugs and other treatments for HIV/AIDS.
He served on numerous public health policy groups including the NIAID AIDS Research Advisory Committee (1991-1995), NIAID’s National Advisory Allergy and Infectious Disease Council (1995-1998), Fair Pricing Coalition, and Board of the Foundation for AIDS.
Photo credit: New York Times